Regeneron Pharmaceuticals, Inc. (REGN)

Sector: Healthcare
Industry: Biotechnology

Current Price

$751.57

Price Bought

$785.51
Trade #9

Analysis Scores

Technical
Fundamental
Total

Technical Indicators

RSI
MACD

Fundamental Metrics

P/E Ratio
18.09
PEG Ratio
1.59
Debt/Equity
9.51
ROE
14.86%

Holdings Analysis

Short Interest: 2.7% (+0.3%)
Insider Holdings: 2.0% (+0.0%)
Institutional Holdings: 91.4% (+0.4%)

Trade History

Trade #9
Buy Date: 2026-02-07
$785.51
Sell Date: 2026-03-09
$759.96
Sold: 2026-03-09
-3.25%
Trade #50
Buy Date: 2026-03-25
$750.17
Sell Date: 2026-04-03
$761.85
Sold: 2026-04-03
1.56%
Trade #76
Buy Date: 2026-04-17
$750.57
Sell Date: 2026-04-25
$751.57
Sold: 2026-04-25
0.13%

Recent News & Sentiment

Regeneron Shares Tumble Premarket After Fianlimab Study Failure

Regeneron Shares Tumble Premarket After Fianlimab Study Failure...

2026-05-18 negative (0.94)
New Drone Incidents in Middle East Keep Tensions High, Nudge US Equity Futures Pre-Bell Lower

New Drone Incidents in Middle East Keep Tensions High, Nudge US Equity Futures Pre-Bell Lower...

2026-05-18 negative (0.74)
Regeneron faces Wall Street downgrades after high-profile melanoma drug fails to beat Merck's Keytruda

Regeneron faces Wall Street downgrades after high-profile melanoma drug fails to beat Merck's Keytruda...

2026-05-18 negative (0.97)
Here Are Monday’s Top Wall Street Analyst Research Calls: Applied Materials, CoreWeave, Deckers Outdoor, F5, Lam Research, Salesforce, ServiceNow, Zscaler, and More

Here Are Monday’s Top Wall Street Analyst Research Calls: Applied Materials, CoreWeave, Deckers Outdoor, F5, Lam Research, Salesforce, ServiceNow, Zscaler, and More...

2026-05-18 neutral (0.94)
Regeneron Melanoma Drug Trial Disappoints and Shares Slide

Regeneron Melanoma Drug Trial Disappoints and Shares Slide...

2026-05-18 negative (0.74)
Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck’s Keytruda

Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck’s Keytruda...

2026-05-18 negative (0.96)
Regeneron slides after melanoma study misses key endpoint (REGN)

Regeneron slides after melanoma study misses key endpoint (REGN)...

2026-05-18 neutral (0.60)
Stocks to Watch: Dominion, NextEra, UnitedHealth

Stocks to Watch: Dominion, NextEra, UnitedHealth...

2026-05-18 neutral (0.94)
Regeneron shares fall 12% on disappointing melanoma trial data

Regeneron shares fall 12% on disappointing melanoma trial data...

2026-05-18 negative (0.97)
3 Reasons to Sell REGN and 1 Stock to Buy Instead

3 Reasons to Sell REGN and 1 Stock to Buy Instead...

2026-05-18 neutral (0.95)